| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Laboratory of Molecular Gastroenterology and Hepatology, 1st Department of Medicine, 2 Department of Pathology, and 3 Research Group of Molecular Oncology, Department of General Surgery, UKSHCampus Kiel, Kiel, Germany
Pancreatic ductal carcinoma is characterized by a profound chemoresistance. As we have shown previously, these tumor cells can develop chemoresistance by interleukin (IL)-1ß in an autocrine and nuclear factor-
B-dependent fashion. Because pancreatic ductal carcinoma contains many mesenchymal stromal cells, we further investigated how tumorstroma interactions contribute to chemoresistance by using a transwell coculture model, including murine pancreatic fibroblasts and the chemosensitive human pancreatic carcinoma cell lines T3M4 and PT45-P1. If cultured with fibroblast-conditioned medium or kept in coculture with fibroblasts, both cell lines became much less sensitive toward treatment with etoposide than cells cultured under standard conditions. Furthermore, the secretion of IL-1ß in T3M4 and PT45-P1 cells was increased by the fibroblasts, and IL-1ß-receptor blockade abolished the resistance-inducing effect during cocultivation. This stimulated IL-1ß secretion could be attributed to nitric oxide (NO) released by the fibroblasts as an IL-1ß-inducing factor. Although both tumor cells secreted only little NO, which was in line with undetectable inducible nitric oxide synthase (iNOS) expression, fibroblasts exhibited significant iNOS expression and NO secretion that could be further induced by the tumor cells. Incubation of T3M4 and PT45-P1 cells with the NO donor S-Nitroso-N-acetyl-D,L-penicillamine up-regulated IL-1ß secretion and conferred resistance toward etoposide-induced apoptosis. Conversely, the resistance-inducing effect of the fibroblasts was significantly abolished, when the specific iNOS inhibitor aminoguanidine was added during coculture. Immunohistochemistry on tissue sections from human pancreatic ductal carcinoma also revealed iNOS expression in stromal cells and IL-1ß expression in tumor cells, thus supporting the in vitro findings. These data clearly demonstrate that fibroblasts contribute to the development of chemoresistance in pancreatic carcinoma cells via increased secretion of NO, which in turn leads to an elevated release of IL-1ß by the tumor cells. These findings substantiate the implication of tumorstromal interactions in the chemoresistance of pancreatic carcinoma.
This article has been cited by other articles:
![]() |
C. Zhang, L. Fu, J. Fu, L. Hu, H. Yang, T.-H. Rong, Y. Li, H. Liu, S.-B. Fu, Y.-X. Zeng, et al. Fibroblast Growth Factor Receptor 2-Positive Fibroblasts Provide a Suitable Microenvironment for Tumor Development and Progression in Esophageal Carcinoma Clin. Cancer Res., June 15, 2009; 15(12): 4017 - 4027. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Geismann, M. Morscheck, D. Koch, F. Bergmann, H. Ungefroren, A. Arlt, M.-S. Tsao, M. G. Bachem, P. Altevogt, B. Sipos, et al. Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor {beta}1- and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer Cancer Res., May 15, 2009; 69(10): 4517 - 4526. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Egberts, V. Cloosters, A. Noack, B. Schniewind, L. Thon, S. Klose, B. Kettler, C. von Forstner, C. Kneitz, J. Tepel, et al. Anti-Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis Cancer Res., March 1, 2008; 68(5): 1443 - 1450. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Hwang, T. Moore, T. Arumugam, V. Ramachandran, K. D. Amos, A. Rivera, B. Ji, D. B. Evans, and C. D. Logsdon Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression Cancer Res., February 1, 2008; 68(3): 918 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Q. Zhu, S. N. Popova, E. R. S. Brown, D. Barsyte-Lovejoy, R. Navab, W. Shih, M. Li, M. Lu, I. Jurisica, L. Z. Penn, et al. Integrin {alpha}11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells PNAS, July 10, 2007; 104(28): 11754 - 11759. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mahadevan and D. D. Von Hoff Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hwu, A. Y. Bedikian, and E. A. Grimm Challenges of chemosensitivity testing. Clin. Cancer Res., September 15, 2006; 12(18): 5258 - 5259. [Full Text] [PDF] |
||||
![]() |
X. Zhang, E. Galardi, M. Duquette, J. Lawler, and S. Parangi Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model Clin. Cancer Res., August 1, 2005; 11(15): 5622 - 5630. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Jhandier, E. A. Kruglov, E. G. Lavoie, J. Sevigny, and J. A. Dranoff Portal Fibroblasts Regulate the Proliferation of Bile Duct Epithelia via Expression of NTPDase2 J. Biol. Chem., June 17, 2005; 280(24): 22986 - 22992. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Graziano, A. Ruzzo, D. Santini, B. Humar, G. Tonini, V. Catalano, R. Berardi, F. Pizzagalli, F. Arduini, I. Bearzi, et al. Prognostic Role of Interleukin-1{beta} Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer J. Clin. Oncol., April 1, 2005; 23(10): 2339 - 2345. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Muerkoster, A. Arlt, B. Sipos, M. Witt, M. Grossmann, G. Kloppel, H. Kalthoff, U. R. Folsch, and H. Schafer Increased Expression of the E3-Ubiquitin Ligase Receptor Subunit {beta}TRCP1 Relates to Constitutive Nuclear Factor-{kappa}B Activation and Chemoresistance in Pancreatic Carcinoma Cells Cancer Res., February 15, 2005; 65(4): 1316 - 1324. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Subhi, B. Tang, B. R. Balsara, D. A. Altomare, J. R. Testa, H. S. Cooper, J. P. Hoffman, N. J. Meropol, and W. D. Kruger Loss of Methylthioadenosine Phosphorylase and Elevated Ornithine Decarboxylase Is Common in Pancreatic Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7290 - 7296. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sato, N. Maehara, and M. Goggins Gene Expression Profiling of Tumor-Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts Cancer Res., October 1, 2004; 64(19): 6950 - 6956. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |